Two–for–one on potential therapies

Ke Zhang () and Jeffrey D. Rothstein ()
Additional contact information
Ke Zhang: Ke Zhang and Jeffrey D. Rothstein are at the Brain Science Institute, Johns Hopkins University, Baltimore, Maryland 21205, USA.
Jeffrey D. Rothstein: Ke Zhang and Jeffrey D. Rothstein are at the Brain Science Institute, Johns Hopkins University, Baltimore, Maryland 21205, USA.

Nature, 2017, vol. 544, issue 7650, 302-303

Abstract: Molecules that inhibit the synthesis of the ataxin 2 protein can ameliorate the effects of two neurodegenerative diseases in mouse models, raising hopes for the success of this approach in clinical trials. See Letters p.362 & p.367

Date: 2017
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature21911 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:544:y:2017:i:7650:d:10.1038_nature21911

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature21911

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().